Significance of data analysis in the quality control of prenatal screening for Down syndrome

被引：7

作者：

Li, Yahong ^{[1
]}

Zhang, Xiaojuan ^{[1
]}

Hong, Dongyang ^{[1
]}

Guan, Xianwei ^{[1
]}

Lv, Shaolei ^{[2
]}

Sun, Yun ^{[1
]}

Jiang, Tao ^{[1
]}

机构：

[1] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Ctr Prenatal Diag, Affiliated Obstet & Gynecol Hosp, 123 Tianfei Rd, Nanjing 210004, Jiangsu, Peoples R China

[2] Zhejiang Biosan Biochem Technol Co Ltd, Hangzhou 310000, Zhejiang, Peoples R China

来源：

BIOMEDICAL REPORTS | 2018年 / 8卷 / 05期

基金：

中国国家自然科学基金;

关键词：

quality control; prenatal screening; Down syndrome;

D O I：

10.3892/br.2018.1078

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Dual detection of alpha-fetoprotein (AFP) and free beta-human chorionic gonadotropin (beta-HCG) is a common screening method for Down syndrome in the second trimester and its efficacy is assessed by false-positive rate (FPR). The present study aimed to investigate the effects of the bias in median multiple of the median (mMoM) values of AFP and free beta-HCG on FPR. The bias in mMoM values of AFP and free beta-HCG and the bias in mMoM values under different gestational ages and weight groups were analyzed. Median equations were adjusted, and medians in LifeCycle software were replaced by local medians. Following two adjustments of the median equations, all indices including FPR, mMoM values of markers and mMoM values under different gestational ages and weight groups generally reached an ideal state. In conclusion, abnormal bias in mMoM values may prompt aberrant application of median equations, and regular monitoring of these indicators may be important for quality control in prenatal screening.

引用

页码：447 / 453

页数：7

共 14 条

[1] n Mid-Trimester Maternal Serum hCG and Alpha Fetal Protein Levels: Clinical Significance and Prediction of Adverse Pregnancy Outcome [J].

Androutsopoulos, Georgios ;

Gkogkos, Panagiotis ;

Decavalas, Georgios .

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2013, 11 (02) :102-106

[2] THE EFFECTS OF GESTATION DATING ON THE CALCULATION OF PATIENT-SPECIFIC RISKS IN DOWNS-SYNDROME SCREENING [J].

BISHOP, J ;

DUNSTAN, FDJ ;

NIX, BJ ;

REYNOLDS, TM .

ANNALS OF CLINICAL BIOCHEMISTRY, 1995, 32 :464-477

[3]

Duan Y, 2014, CLIN EXP OBSTET GYN, V41, P572

[4] Second-trimester maternal serum screening for Down's syndrome:: free β-human chorionic gonadotrophin (HCG) and α-fetoprotein, with or without unconjugated oestriol, compared with total HCG, α-fetoprotein and unconjugated oestriol [J].

Extermann, P ;

Bischof, P ;

Marguerat, P ;

Mermillod, B .

HUMAN REPRODUCTION, 1998, 13 (01) :220-223

[5] Factors Influencing Prenatal Screening for Down's Syndrome: Evidence From Zhejiang (China) [J].

Huang, Jiayan ;

Chen, Yingyao ;

Pong, Raymond W. .

ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH, 2015, 27 (02) :NP1288-NP1297

[6] Monitoring surgical and medical outcomes: the Bernoulli cumulative SUM chart. A novel application to assess clinical interventions [J].

Leandro, G ;

Rolando, N ;

Gallus, G ;

Rolles, K ;

Burroughs, AK .

POSTGRADUATE MEDICAL JOURNAL, 2005, 81 (960) :647-652

[7]

Li YH, 2017, MOL CLIN ONCOL, V7, P623, DOI 10.3892/mco.2017.1355

[8] The impact of bias in MoM values on patient risk and screening performance for Down syndrome [J].

Nix, Barry ;

Wright, Dave ;

Baker, Amy .

PRENATAL DIAGNOSIS, 2007, 27 (09) :840-845

[9] Cumulative summation (CUSUM) charts in the monitoring of hypospadias outcomes: A tool for quality improvement initiative [J].

Parikh, A. M. ;

Park, A. M. ;

Sumfest, J. .

JOURNAL OF PEDIATRIC UROLOGY, 2014, 10 (02) :306-311

[10] The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns [J].

Sayam, N. Cenk ;

Canda, M. Tunc ;

Ahmet, Newze ;

Arda, Sezer ;

Suet, Necdet ;

Varol, Fuesun G. .

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2008, 277 (01) :47-53

← 1 2 →